Tag Archives: bxlt

Halozyme Enzyme Could Boost Power Of Cancer Drugs

Halozyme Therapeutics has been one of 2015’s hotter biotech stocks, but it’s not exactly because of developing a drug. Halozyme’s (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanz for the same purpose to such drug companies as Pfizer (PFE), Roche (RHHBY), Johnson & Johnson ‘s (JNJ) Janssen division, AbbVie (ABBV) and Baxalta (BXLT) for the development of new injectable products. San

Shire Offers $30 Billion For Ex-Baxter Unit Baxalta

Barely after it hatched as an independent company, drugmaker Baxalta (BXLT) got an unsolicited $30 billion buyout proposal from Shire (SHPG), sending its stock up sharply in early trading Tuesday. Shire said that on July 10 it proposed an all-stock transaction exchanging 0.1687 Shire ADR for every share of Baxalta, which implies a value of $45.23 a share based on Shire’s current price. That would represent a 36% premium over the Monday closing